Variables | RP+/DU−/PAH− | p | |
2005, n = 344 | 2009, n = 410 | ||
All | 59.7 | 59.9 | 0.956 |
CCI | 61.3 | 53.2 | 0.027 |
PDE5 inhibitors | 0.6 | 1.5 | 0.302 |
ET1RA | 0.9 | 5.1 | < 0.001 |
ACE inhibitors | 19.0 | 20.5 | 0.502 |
AT1RA | 5.5 | 13.7 | < 0.0001 |
Pentoxifylline | 20.3 | 7.1 | < 0.0001 |
IV prostanoids | 14.8 | 25.1 | < 0.001 |
Variables | DU+/PAH− | p | |
2005, n = 141 | 2009, n = 199 | ||
All | 77.5 | 75.4 | 0.661 |
CCI | 62.4 | 45.2 | 0.002 |
PDE5 inhibitors | 1.4 | 5.5 | 0.082 |
ET1RA | 3.5 | 19.6 | < 0.0001 |
ACE inhibitors | 20.9 | 24.3 | 0.437 |
AT1RA | 2.8 | 7.5 | 0.092 |
Pentoxifylline | 12.8 | 11.1 | 0.733 |
IV prostanoids | 27.7 | 30.7 | 0.629 |
Variables | PAH+/DU− | p | |
2005, n = 68 | 2009, n = 78 | ||
All | 77.2 | 89.6 | 0.023 |
CCI | 45.6 | 47.4 | 0.869 |
PDE5 inhibitors | 14.7 | 16.7 | 0.822 |
ET1RA | 23.5 | 17.9 | 0.420 |
ACE inhibitors | 30.7 | 41.7 | 0.138 |
AT1RA | 10.3 | 12.8 | 0.797 |
Pentoxifylline | 26.5 | 3.8 | < 0.0001 |
IV prostanoids | 4.4 | 23.1 | 0.002 |
Significant data are in bold face. ACE: angiotensin-converting enzyme; PDE5: phosphodiesterase type 5; CCI: calcium channel inhibitors; ET1RA: endothelin 1 receptor antagonists; AT1RA: angiotensin 1 receptor antagonists; IV: intravenous; RP: Raynaud phenomenon; DU: digital ulcers; PAH: pulmonary arterial hypertension.